TY - JOUR
T1 - Psychometric methods for diagnosing and monitoring minimal hepatic encephalopathy
T2 - current validation level and practical use
AU - Hansen, Mads Kingo Guldberg
AU - Kjærgaard, Kristoffer
AU - Eriksen, Lotte Lindgreen
AU - Grønkjær, Lea Ladegaard
AU - Mikkelsen, Anne Catrine Daugaard
AU - Sandahl, Thomas Damgaard
AU - Vilstrup, Hendrik
AU - Thomsen, Karen Louise
AU - Lauridsen, Mette Munk Enok
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/3
Y1 - 2022/3
N2 - Hepatic encephalopathy (HE) is cerebral dysfunction caused by liver failure and inflicts 30-40% of patients with liver cirrhosis during their disease course. Clinically manifest HE is often preceded by minimal HE (MHE) — a clinically undetectable cognitive disturbance closely associated with loss of quality of life. Accordingly, detecting and treating MHE improve the patients’ daily functioning and prevent HE-related hospital admissions. The scope of this review article is to create an overview of the validation level and usage of psychometric tests used to detect MHE: Portosystemic hepatic encephalopathy test, continuous reaction time test, Stroop EncephalApp, animal naming test, critical flicker frequency test, and inhibitory control test. Our work is aimed at the clinician or scientist who is about to decide on which psychometric test would fit best in their clinic, cohort, or study. First, we outline psychometric test validation obstacles and requirements. Then, we systematically approach the literature on each test and select well-conducted studies to answer the following questions: • Which percentage of patients with cirrhosis does the test deem as having MHE? • Is the test able to predict clinically manifest HE? • Is there a well-known test-retest variation and inter-observer variation? • Is the test able to detect a treatment response? • Is the test result affected by age, educational level, gender, or comorbidities?
AB - Hepatic encephalopathy (HE) is cerebral dysfunction caused by liver failure and inflicts 30-40% of patients with liver cirrhosis during their disease course. Clinically manifest HE is often preceded by minimal HE (MHE) — a clinically undetectable cognitive disturbance closely associated with loss of quality of life. Accordingly, detecting and treating MHE improve the patients’ daily functioning and prevent HE-related hospital admissions. The scope of this review article is to create an overview of the validation level and usage of psychometric tests used to detect MHE: Portosystemic hepatic encephalopathy test, continuous reaction time test, Stroop EncephalApp, animal naming test, critical flicker frequency test, and inhibitory control test. Our work is aimed at the clinician or scientist who is about to decide on which psychometric test would fit best in their clinic, cohort, or study. First, we outline psychometric test validation obstacles and requirements. Then, we systematically approach the literature on each test and select well-conducted studies to answer the following questions: • Which percentage of patients with cirrhosis does the test deem as having MHE? • Is the test able to predict clinically manifest HE? • Is there a well-known test-retest variation and inter-observer variation? • Is the test able to detect a treatment response? • Is the test result affected by age, educational level, gender, or comorbidities?
KW - Diagnostic tests
KW - Hepatic encephalopathy
KW - Liver cirrhosis
KW - Psychometric tests
KW - Test validation
U2 - 10.1007/s11011-022-00913-w
DO - 10.1007/s11011-022-00913-w
M3 - Journal article
C2 - 35102491
AN - SCOPUS:85123959806
VL - 37
SP - 589
EP - 605
JO - Metabolic Brain Disease
JF - Metabolic Brain Disease
SN - 0885-7490
IS - 3
ER -